Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CCR4 | P51679 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808286 | 1.00 | KMT2A (0.50) | KMT2AMEN1CCR4SIGMAR1HDAC8 | |
| SCHEMBL4914651 | 0.86 | HDAC8 (0.50) | HDAC8PTPN1NAMPT | |
| SCHEMBL4925914 | 0.86 | HDAC8 (0.48) | HDAC8PTPN1POLBNAMPT | |
| SCHEMBL6238826 | 0.79 | HDAC8 (0.70) | HDAC8PTPN1NAMPT | |
| SCHEMBL4922008 | 0.79 | HDAC8 (0.51) | HDAC8PTPN1NAMPT | |
| SCHEMBL14002110 | 0.78 | EPHX2 (0.57) | KMT2ANAMPTDRD2DRD4DRD3 | |
| SCHEMBL915402 | 0.78 | KMT2A (0.65) | KMT2AMEN1SIGMAR1POLBMAOB | |
| SCHEMBL22962110 | 0.77 | HDAC8 (0.57) | HDAC8PTPN1 | |
| SCHEMBL14002108 | 0.76 | DCUN1D1 (0.66) | KMT2ASIGMAR1POLB | |
| SCHEMBL14183936 | 0.76 | HDAC8 (0.62) | HDAC8PTPN1POLBNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446115-B2 | To treat pain, drug addiction, or tinnitus; selectively inhibit sodium or calcium ion channels and agonize or antagonize mu -opioid receptors; N-Benzyl-N-(2-dimethylamino-ethyl)-2-(S)-[3-(4-fluorophenyl)-ureido]-3-methyl-butyramide | SEPRACOR, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446115-B2 | To treat pain, drug addiction, or tinnitus; selectively inhibit sodium or calcium ion channels and agonize or antagonize mu -opioid receptors; N-Benzyl-N-(2-dimethylamino-ethyl)-2-(S)-[3-(4-fluorophenyl)-ureido]-3-methyl-butyramide | SEPRACOR, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446115-B2 | To treat pain, drug addiction, or tinnitus; selectively inhibit sodium or calcium ion channels and agonize or antagonize mu -opioid receptors; N-Benzyl-N-(2-dimethylamino-ethyl)-2-(S)-[3-(4-fluorophenyl)-ureido]-3-methyl-butyramide | SEPRACOR, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070093522-A1 | Peptidomimetic ligands for cellular receptors and ion channels | PERSONS PAUL E | 2007-04-26 | — | — | US | disclosed |
| US-20070093522-A1 | Peptidomimetic ligands for cellular receptors and ion channels | PERSONS PAUL E | 2007-04-26 | — | — | US | disclosed |
| US-20070093522-A1 | Peptidomimetic ligands for cellular receptors and ion channels | PERSONS PAUL E | 2007-04-26 | — | — | US | disclosed |
| US-7115664-B2 | Peptidomimetic ligands for cellular receptors and ion channels | SEPRACOR INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050080271-A1 | Peptidomimetic ligands for cellular receptors and ion channels | SEPRACOR INC. | 2005-04-14 | — | — | US | disclosed |
| WO-2001070684-A2 | PEPTIDOMIMETIC LIGANDS FOR CELLULAR RECEPTORS AND ION CHANNELS | SEPRACOR, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093522-A1 | Peptidomimetic ligands for cellular receptors and ion channels | OPRL1, TRPV1, ORAI1 | KMT2A 2244/4885MEN1 4198/4885CCR4 1095/4885 |
| US-20050080271-A1 | Peptidomimetic ligands for cellular receptors and ion channels | TRPV1, OPRL1, TRPV2 | KMT2A 2630/4885MEN1 4407/4885CCR4 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.